Abstract
E-mail Abstract Author
Add To Itinerary
Session
Search Abstracts
Program

Session 5 Oral Abstract Session
Epidemiology and Infection Control
Session Time: Monday, 10 am - 12:30 pm
Room 6C

10:30   13.
 Lower Mortality in Ambulatory HIV-Infected Patients who Initiate Antiretroviral Therapy at Higher CD4+ Cell Counts
F. Palella*1, M. Knoll1, J. Chmiel1, A. Moorman2, K. Wood3, A. Greenberg2, and S. Holmberg2 for the HIV Outpatient Study (HOPS) Investigators
1Northwestern Univ., Chicago, IL; 2CDC, Atlanta, GA; and 3Cerner Corp., Vienna, VA

Background: Optimal timing of antiretroviral therapy (ART) initiation for HIV-infected patients is of great clinical and public health importance, yet remains unclear.  Clinicians variably advocate earlier (higher CD4+ cell count [CD4]) vs later (lower CD4) ART initiation, but sparse data exist to support either strategy.

Methods: Patients well-characterized by CD4 and ART use history from January 1996 to March 2001 at 8 U.S. clinics participating in the HOPS were grouped by pre-ART CD4 into 3 strata: 501-750, 351-500, 201-350 cells/mm3. In a prospective analysis, we compared mortality rates (excluding suicide and trauma) in each pre-ART CD4 stratum for patients who initiated ART while in that stratum to patients who delayed ART until a lower stratum.

Results: Data from 126 patients with CD4 501-750 cells/mm3, 315 with CD4 351-500, and 377 with CD4 201-350 were analyzed.  ART initiators vs delayers within each stratum had many similar demographics. In each of the 3 CD4 strata, more than two-thirds of delayers started ART in the next lower stratum.  Median years of follow-up for initiators and delayers were, respectively, 5.9 and 5.3 for those with CD4 501-750; 3.7 and 3.4 for CD4 351-500; and 3.0 and 3.3 for CD4 201-350 cells/mm3 (p>0.3 for each).  For those with CD4 501-750, 7.5 deaths/1000 person-years occurred in 54 initiators and 3.0/1000 person-years in 72 delayers (rate ratio [RR]=2.52; 95% CI: 0.23, 27.8; p>0.4), but only 3 deaths occurred in this stratum, none apparently HIV-related.  For those with CD4 between 351-500, 229 initiated and 86 delayed ART, with 10.7 and 18.2 deaths/1000 person years, respectively (RR= 0.59; 95% CI: 0.21, 1.65; p>0.3). For those with CD4 201-350, 325 initiated and 52 delayed ART, with 20.8 and 70.6 deaths/1000 person years, respectively (RR= 0.29; 95% CI: 0.15, 0.58; p<.001).

Conclusions:  These preliminary data suggest that initiation of ART for patients with CD4 201-350 cells/mm3, and possibly those with CD4 351-500, is associated with reduction in mortality in comparison with those for whom such therapy is delayed.  Such survival benefits should be considered when evaluating the optimal timing of ART initiation.

 

©2002 9th Conference on Retroviruses and Opportunistic Infections